1. Home
  2. INKT

as of 12-08-2025 4:00pm EST

$12.01
$0.00
0.00%
Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Chart Type:
Time Range:
Founded: 2017 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 51.7M IPO Year: 2021
Target Price: $35.00 AVG Volume (30 days): 18.9K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.02 EPS Growth: N/A
52 Week Low/High: $4.56 - $76.00 Next Earning Date: 11-14-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered INKT Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 18 hours ago

AI Recommendation

hold
Model Accuracy: 67.57%
67.57%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: